The AdvisorShares Pure US Cannabis ETF (MSOS) just posted its strongest run since its 2026 low, and the timing isn't an accident. Investors are positioning ahead of a DEA administrative hearing set for June 29, one that will determine whether adult-use cannabis products join medical marijuana on Schedule III. Trulieve's move to the New York Stock Exchange this week has become the clearest signal yet that federal cannabis policy is inching toward something operators can actually plan around.
MSOS delivered a 103.7% one-year NAV return through May 31, dwarfing the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8%. That kind of divergence tells you capital is chasing a specific catalyst, not just riding a broad market wave. For multi-state operators watching from the sidelines, the bigger story sits underneath the ticker symbols: compliance infrastructure, tax treatment, and banking access are all shifting at once, and back-office systems built on tools like the best-rated cannabis dispensary software illinois operators rely on for seed-to-sale tracking will need to keep pace with faster-moving capital markets and tighter reporting expectations. best-rated cannabis dispensary software illinois
Why Trulieve's Listing Actually Matters
Trulieve, MSOS' largest holding at roughly 30% of assets, separated its medical cannabis operations from its adult-use business specifically to clear the bar for a senior exchange listing. That's not a cosmetic restructuring. Splitting entities this way changes how revenue gets reported, how lenders assess risk, and how the company handles 280E tax exposure across different business lines. CEO Kim Rivers tied the milestone directly to the federal move shifting medical marijuana to Schedule III, a policy shift that, in practice, opened a door that had been welded shut for cannabis companies seeking access to mainstream exchanges.
Alliance Global's bullish stance on Trulieve rests partly on its concentration in medical-only states and expansion into Texas and Georgia. That's a meaningful distinction for operators evaluating their own state footprints: medical-only markets carry different licensing structures, different patient verification requirements, and often steadier margins than adult-use markets saturated with competing dispensaries.
The Schedule III Mechanism, Explained Plainly
Here's the catch that often gets glossed over in market coverage: Schedule III reclassification doesn't legalize cannabis federally. What it does is remove the 280E tax penalty that has forced state-licensed cannabis businesses to pay taxes on gross income rather than net profit, unable to deduct ordinary expenses like payroll, rent, and marketing. Acting Attorney General Todd Blanche's April action applied this relief to state-licensed medical marijuana products and opened the broader rescheduling process now headed to hearing.
For dispensary operators and MSOs alike, that tax shift alone can free up real cash flow. Roth Capital called the move "extremely favorable," pointing to improved capital access and a path toward future uplistings. Cresco Labs' $50 million revolving credit facility from Needham Bank, secured this week, is an early example of what that improved access looks like in practice - non-dilutive financing that CEO Charlie Bachtell says positions the company for a future senior exchange listing.
Reading the Upside Numbers With Some Caution
Analyst price targets circulating across MSOS holdings show wide dispersion. Verano carries the steepest projected upside at 195%, followed by Jushi Holdings near 183% and Cresco Labs close to 99%. Green Thumb Industries, at 70% upside, outpaces both Trulieve and Curaleaf on that metric despite Trulieve's larger portfolio weighting.
Retail sentiment on platforms like Stocktwits runs extremely bullish across most of these names, with heavy message volume accompanying the enthusiasm. That's worth flagging for what it is: sentiment, not a certainty. Price targets reflect analyst models built on assumptions about rescheduling outcomes and uplisting timelines, not guaranteed results. The June 29 hearing could run through mid-July, and administrative proceedings of this scale rarely move in a straight line.
What Operators Should Actually Watch
- Whether the DEA hearing produces a firm timeline for Schedule III implementation, or further delay
- How uplisting eligibility rules apply to companies with mixed medical and adult-use operations
- Whether expanded capital access translates into better wholesale pricing and inventory financing for smaller operators, not just the largest MSOs
- How banking relationships evolve as institutional investors gain more comfort with the sector
None of this changes day-to-day compliance obligations. Lab testing, COA verification, compliant packaging, and age-gated retail access remain state-level requirements regardless of what happens at the federal level. What could change is the financial runway operators have to invest in those systems, and that's the distinction worth tracking as the hearing date approaches.
